Page last updated: 2024-08-24

lurtotecan and Leukemia, Myeloid

lurtotecan has been researched along with Leukemia, Myeloid in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Albitar, M; Barrett, E; Cortes, JE; Garcia-Manero, G; Giles, FJ; Hamilton, M; Kantarjian, HM; Tallman, MS; Thomas, DA; Verstovsek, S; Wierda, WG	1

Trials

1 trial(s) available for lurtotecan and Leukemia, Myeloid

Article	Year
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia. Cancer, 2004, Apr-01, Volume: 100, Issue:7 Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Topoisomerase I Inhibitors; Treatment Outcome	2004

Article

Year

Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.

Cancer, 2004, Apr-01, Volume: 100, Issue:7

Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Middle Aged; Mouth Mucosa; Topoisomerase I Inhibitors; Treatment Outcome

2004